European Haemophilia Consortium: Day 1 At EHC Conference 2025 In Vienna – What A Start
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Day 1 at EHC Conference 2025 in Vienna – What a Start
We kicked off with insights into haemophilia care in Austria, celebrating six decades of advocacy from Österreichische Hämophilie Gesellschaft (ÖHG), the Austrian Haemophilia Society, and learning from their national registry and treatment guidelines.
A powerful session on women’s health and bleeding disorders broke down barriers with discussions on diagnosis, menopausal management, and inspiring patient perspectives from symptomatic carriers.
The afternoon dove deep into von Willebrand Disease, exploring family mental health, the latest in genetics and screening, and a sneak peek at future treatments.
The day wrapped up with our General Assembly, where EHC National Member Organisation representatives came together for important discussions and decisions about our community’s future.
Thank you to our brilliant chairs, speakers, and all attendees. Looking forward to tomorrow’s sessions.”
Keep up with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis